Rocket Pharmaceuticals
Rocket Pharmaceuticals is developing genetic therapies to treat complex and rare life-threatening disorders, with a focus on curative gene therapies and early diagnosis of genetic diseases.
Services
Rocket Pharmaceuticals is advancing an integrated pipeline of genetic therapies designed to correct the root causes of complex and rare life-threatening disorders. Their services include the development and clinical trials of gene therapy treatments for various diseases, including Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Danon Disease, Pyruvate Kinase Deficiency (PKD), PKP2 arrhythmogenic cardiomyopathy (ACM), and BAG3-associated dilated cardiomyopathy (DCM).
Mission and Vision
The mission of Rocket Pharmaceuticals is to develop first-in-class and best-in-class, curative gene therapies for patients with devastating diseases. Their vision, expressed as 'Seeking Gene Therapy Cures,' underpins their strategic approach to creating long-term solutions and sustainable treatments for rare genetic disorders.
Values
Rocket Pharmaceuticals operates on core values that include Trust, Generosity, Curiosity, and Elevate. These values guide their interactions, research priorities, and business practices, fostering a culture that emphasizes collaboration, innovation, and the pursuit of life-changing medical solutions.
Locations and Facilities
Rocket Pharmaceuticals' R&D and Corporate Headquarters are located at 9 Cedarbrook Drive, Cranbury, NJ 08512. They also maintain an office in The Empire State Building at 350 Fifth Avenue, Suite 7530, New York, NY 10118. Their state-of-the-art manufacturing facility, located in Cranbury, New Jersey, spans approximately 103,720 square feet and was constructed in 2022 to meet their specific manufacturing needs.
Partnerships and Collaborations
Rocket Pharmaceuticals is a founding member of the BeginNGS™ consortium, partnering with Rady Children’s Institute for Genomic Medicine to drive early diagnosis of rare genetic diseases. They have also partnered with genetic testing leader Invitae to advance the Invitae Unlock™ Cardiomyopathy and Arrhythmia testing program, which aims to accelerate the early and accurate diagnosis of genetic cardiovascular disease.